Related CAS #
228546-92-7 (CR 665 free base)
Synonym
CR-665; FE-200665; JNJ-38488502; CR665; FE200665; JNJ38488502; CR 665; FE 200665; JNJ 38488502;
IUPAC/Chemical Name
(R)-2-((R)-2-((R)-2-amino-3-phenylpropanamido)-3-phenylpropanamido)-N-((R)-1-amino-5-guanidino-1-oxopentan-2-yl)-N-(pyridin-4-ylmethyl)hexanamide acetate
InChi Key
HJWCYDYBEQFBNK-CKYFGSNBSA-N
InChi Code
InChI=1S/C36H49N9O4.C2H4O2/c1-2-3-15-29(35(49)45(24-27-17-20-41-21-18-27)31(32(38)46)16-10-19-42-36(39)40)43-34(48)30(23-26-13-8-5-9-14-26)44-33(47)28(37)22-25-11-6-4-7-12-25;1-2(3)4/h4-9,11-14,17-18,20-21,28-31H,2-3,10,15-16,19,22-24,37H2,1H3,(H2,38,46)(H,43,48)(H,44,47)(H4,39,40,42);1H3,(H,3,4)/t28-,29-,30-,31-;/m1./s1
SMILES Code
N=C(N)NCCC[C@H](C(N)=O)N(C([C@@H](CCCC)NC([C@@H](CC1=CC=CC=C1)NC([C@@H](CC2=CC=CC=C2)N)=O)=O)=O)CC3=CC=NC=C3.CC(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
731.90
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Olesen AE, Kristensen K, Staahl C, Kell S, Wong GY, Arendt-Nielsen L, Drewes AM. A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone. Clin Pharmacokinet. 2013 Feb;52(2):125-37. doi: 10.1007/s40262-012-0023-8. PubMed PMID: 23212610.
2: Arendt-Nielsen L, Olesen AE, Staahl C, Menzaghi F, Kell S, Wong GY, Drewes AM. Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009 Sep;111(3):616-24. doi: 10.1097/ALN.0b013e3181af6356. PubMed PMID: 19672186.
3: Hughes FM Jr, Shaner BE, Brower JO, Woods RJ, Dix TA. Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain. Open Med Chem J. 2013 Nov 4;7:16-22. doi: 10.2174/1874104501307010016. PubMed PMID: 24222801; PubMed Central PMCID: PMC3821081.
4: Vanderah TW, Largent-Milnes T, Lai J, Porreca F, Houghten RA, Menzaghi F, Wisniewski K, Stalewski J, Sueiras-Diaz J, Galyean R, Schteingart C, Junien JL, Trojnar J, Rivière PJ. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol. 2008 Mar 31;583(1):62-72. doi: 10.1016/j.ejphar.2008.01.011. PubMed PMID: 18282565.
5: Vadivelu N, Mitra S, Hines RL. Peripheral opioid receptor agonists for analgesia: a comprehensive review. J Opioid Manag. 2011 Jan-Feb;7(1):55-68. Review. PubMed PMID: 21434585.
6: Binder W, Machelska H, Mousa S, Schmitt T, Rivière PJ, Junien JL, Stein C, Schäfer M. Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology. 2001 Jun;94(6):1034-44. PubMed PMID: 11465595.
